21 results match your criteria: "Maggiore Hospital-AUSL Bologna[Affiliation]"

In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval for cisplatin-unfit patients. In our work, we deeply analyzed the results of the three pivotal studies in view of the rapidly evolving therapeutic advanced UC's scenario.

View Article and Find Full Text PDF

Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study.

Cancers (Basel)

November 2024

Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.

: Glioblastoma -wildtype (GBM -wt) is the most aggressive brain tumor in adults and is characterized by an immunosuppressive microenvironment. Different factors shaping its tumor microenvironment (TME) regulate tumor progression and treatment response. The aim of this study was to characterize the main immunosuppressive elements of the GBM -wt TME.

View Article and Find Full Text PDF

Advances in Diagnosis of Skin and Superficial Tissue Disorders-"Old and Emerging" Diagnostic Tools.

Diagnostics (Basel)

October 2024

Pathology Unit, DIAP-Dipartimento InterAziendale di Anatomia Patologica di Bologna, Maggiore Hospital-AUSL Bologna, 40133 Bologna, Italy.

Skin and superficial tissue disorders (SSTDs) are some of the most common diseases affecting humans [...

View Article and Find Full Text PDF

Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.

J Thorac Oncol

October 2024

Thoracic Surgery Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) "Regina Elena" National Cancer Institute, Rome, Italy; Division of Thoracic Surgery, McGill University Health Centre, Montreal, QC, Canada. Electronic address:

Article Synopsis
  • Neoadjuvant chemoimmunotherapy is changing the treatment for resectable non-small cell lung cancer (NSCLC), but the importance of pathologic response is still uncertain.
  • A systematic review and individual patient data meta-analysis was conducted to assess how achieving complete pathologic response (pCR) or major pathologic response (MPR) affects long-term survival (EFS) and examine the role of adjuvant immunotherapy.
  • The findings showed that patients who achieved pCR or MPR had significantly better EFS rates, while adjuvant immunotherapy did not improve survival outcomes post-surgery.
View Article and Find Full Text PDF
Article Synopsis
  • Embryonic-type neuroectodermal tumor (ENT) is a type of cancer involving the overgrowth of embryonic neuroectodermal tissue, making diagnosis difficult due to its mix with other tumor components.
  • This study focused on the immunohistochemical characteristics of ENT, embryonic-type neuroectodermal tissue (EtNT), and mature neuro-glial tissue (MNGT) to enhance diagnostic accuracy.
  • The researchers found SOX2 to be the most effective marker for EtNT and suggested a combination of various markers (including SOX11, GFAP, and others) to better identify and quantify EtNT in germ cell tumors.
View Article and Find Full Text PDF

Postchemotherapy postpubertal-type yolk sac tumors (YST) with glandular and solid phenotypes are aggressive and commonly resistant to systemic chemotherapy. These neoplasms show morphologic features that significantly overlap with those of somatic carcinomas with "enteroblastic" or "fetal" phenotype (the preferred terminology depends on the site of origin). They often present as late or very late recurrences, and their diagnosis is challenging because they frequently affect patients in an age group at risk for carcinomas of somatic origin.

View Article and Find Full Text PDF

Histopathology of growth hormone-secreting pituitary tumors: State of the art and new perspectives.

Best Pract Res Clin Endocrinol Metab

May 2024

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy. Electronic address:

Article Synopsis
  • Somatotroph adenomas, a type of pituitary neuroendocrine tumor (PitNET), usually arise from the adenohypophysis and lead to conditions like acromegaly and gigantism, but some variants may be silent and not show obvious symptoms.
  • Histopathological evaluation requires a detailed analysis of the tumor, including its morphology, hormone secretion, and specific markers to understand its origin and potential behavior, especially in cases that don't function typically or are metastatic.
  • Recent studies stress the significance of genetic and epigenetic evaluations in identifying aggressive tumor variants to enhance targeted treatment strategies for pituitary adenomas.
View Article and Find Full Text PDF

Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.

Pathol Res Pract

February 2024

Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. Electronic address:

Background: Identifying biomarkers for metastatic renal cell carcinoma (mRCC) is an unmet need in actual immunotherapy era. Available data regarding chromosome 3p genes (i.e.

View Article and Find Full Text PDF
Article Synopsis
  • * FOXA2 has been identified as a key gene in the development of germ cell tumors, and while it and GATA3 are shown to be useful markers for diagnosing non-sarcomatoid YSTpt, they are not effective for sarcomatoid YSTpt, as the latter demonstrates no expression of FOXA2 and only focal expression of GATA3.
  • * The research suggests that the sarcomato
View Article and Find Full Text PDF

Background: TERT promoter mutation is one of the most common genomic alterations in urothelial carcinoma (UC). Its prognostic role on patients' outcomes is still not clear.

Methods: We performed a single-center retrospective analysis on patients with advanced UC treated with platinum-based chemotherapy or immunotherapy to assess the presence of somatic TERT and TERT mutations and their association with clinicopathologic factors and survival outcomes.

View Article and Find Full Text PDF

Despite the significant improvements in the field of oncological treatments in recent decades, and the advent of targeted therapies and immunotherapy, urothelial carcinoma of the bladder remains a highly heterogeneous and difficult-to-treat neoplasm with a poor prognosis. In this context, owing to the new methods of genomic sequencing, numerous studies have analyzed the genetic features of muscle-invasive bladder cancer, providing a consensus set of molecular classes, to identify malignancies that may respond better to specific treatments (standard chemotherapy, immunotherapy, target therapy, local-regional treatment, or combinations) and improve the survival. The aim of the current review is to provide an overview of the current status of the molecular landscape of muscle-invasive bladder cancer, focusing our attention on therapeutic and prognostic implications in order to select the most effective and tailored therapeutic regimen for the individual patient.

View Article and Find Full Text PDF

The 2022 WHO classification of urinary and male genital tumors introduced several novel kidney entities exhibiting eosinophilic/oncocytic features with specific mutational backgrounds. Thus, molecular techniques, such as next-generation sequencing (NGS), became more commonly used for their evaluation. We studied 12 low-grade oncocytic tumors (LOT) of the kidney (from 11 patients), identified in a cohort of 210 eosinophilic/oncocytic renal tumors, diagnosed in our institution between October 2019 and May 2023, which represented 5.

View Article and Find Full Text PDF

Sertoli cell tumor is a type of testicular sex cord-stromal tumor (TSCST) typically driven by gain-of-function CTNNB1 variants. Recently, molecular studies have identified TSCSTs (including Sertoli cell tumors) with loss-of-function APC variants, raising the possibility that germline APC alterations may predispose to TSCSTs. In this study, we evaluated 4 TSCSTs from 4 individual patients, including 3 APC -mutant neoplasms identified in prior studies (1 in a patient with familial adenomatous polyposis [FAP] and 2 in patients with unknown syndromic status) and 1 tumor of unknown mutational status diagnosed in a patient with known FAP.

View Article and Find Full Text PDF
Article Synopsis
  • Spermatocytic tumors (ST) are rare, mostly benign germ cell tumors found in older men, but some can behave aggressively, especially when they transform into a sarcomatoid form.
  • In a study of 27 samples from 25 patients, researchers identified two genomic subgroups of STs: one with stable genomes and specific RAS/RAF mutations, and another with altered ploidy but no recurrent mutations.
  • Aggressive cases of ST were linked to mutations in the TP53 gene and an increase in chromosome 12p, indicating distinct biologic progression patterns within the tumor types.
View Article and Find Full Text PDF

Aims: Yolk sac tumour postpubertal-type (YSTpt) shows a wide range of histological patterns and is challenging to diagnose. Recently, forkhead box transcription factor A2 (FoxA2) emerged as a driver of YSTpt formation and a promising marker for diagnosing YSTpt. However, FoxA2 has not been tested in the different patterns of YSTpt.

View Article and Find Full Text PDF

TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis.

Pathol Res Pract

July 2023

Pathology Unit, Maggiore Hospital-AUSL Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.

Background: In recent years, several studies focused on the process of reprogramming of seminoma (S) cells, which regulates the transition from pure S (P-S) to S component (S-C) of mixed germ cell tumors of the testis (GCTT) and finally to embryonal carcinoma (EC) and other nonseminomatous GCTT (NS-GCTT). The accepted pathogenetic model is driven and regulated by cells (macrophages, B- and T-lymphocytes) and molecules of the tumor microenvironment (TME). Herein, we tested a series of GCTT with double staining (DS) for CD68-PD-L1 to evaluate tumor-associated macrophages (TAMs) expressing programmed death-ligand 1 (PD-L1) [TAMs PD-L1(+)] and clarify if these cells may be involved in establishing the fate of GCTT.

View Article and Find Full Text PDF

PRAME Expression in Mucosal Melanoma of the Head and Neck Region.

Am J Surg Pathol

May 2023

Pathology Unit, Department of Biomedical and Neuromotor Sciences (DIBINEM), Bellaria Hospital, University of Bologna, Bologna, Italy.

PRAME (PReferentially expressed Antigen in MElanoma), a cancer-testis antigen expressed in normal and neoplastic tissues with several functions, proved to be a useful diagnostic tool in the differential diagnosis between benign and malignant melanocytic lesions. The current study aims to perform PRAME stain on a retrospective case series of mucosal melanocytic tumors of the head and neck region to compare 3 different scores and evaluate the most reliable one in this diagnostic set. Immunohistochemical analysis for PRAME was performed in 54 benign and malignant mucosal melanocytic tumors of the head and neck region collected from 41 patients.

View Article and Find Full Text PDF

H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma.

Pathol Res Pract

February 2023

Pathology Unit, Maggiore Hospital-AUSL Bologna, Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy. Electronic address:

Background: Lymphovascular invasion (LVI) is a relevant prognostic factor in germ cell tumors of the testis (GCTT), and it is included in the pT stage. However, its detection on hematoxylin and eosin (H&E) slides is very challenging, and previous studies reported fair to moderate inter-observer agreement among dedicated uropathologists. In the present study, we tested H&E and a recently developed in-house double staining for OCT4/CD34 to detect LVI in GCTT.

View Article and Find Full Text PDF

Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma?

Pathol Res Pract

January 2023

Pathology Unit, Maggiore Hospital-AUSL Bologna, Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy. Electronic address:

The recently described SWI/SNF complex-deficient sinonasal carcinoma (SMARCB1 & SMARCA4) may exhibit a yolk sac-like morphology. Tumors with similar features (yolk sac-like histology combined with the immunohistochemical loss of SMARCB1/INI1 and/or SMARCA4/BRG1) have also been described in other sites, such as the female genital tract. In this study, we immunohistochemically assessed SMARCB1/INI1 and SMARCA4/BRG1 expression to evaluate if these proteins could be involved in the pathogenesis of testicular yolk sac tumors of postpubertal type (YSTpt).

View Article and Find Full Text PDF

Adult onset egg allergy: a case report.

Clin Mol Allergy

October 2021

SS of Allergology ASL AL, Novi Lingure, AL, Italy.

Background: Egg allergy is one of the most frequent food allergies in childhood while adult onset of egg allergy is a rare condition.

Case Presentation: We report the case of a 30 years old man sent to our center in order to investigate gastrointestinal symptoms occurring since 2 years after egg and derivatives intake. He did not suffer from egg or other food allergies in childhood.

View Article and Find Full Text PDF